stoxline Quote Chart Rank Option Currency Glossary
  
Jupiter Neurosciences, Inc. (JUNS)
0.8825  -0.026 (-2.81%)    02-12 19:54
Open: 0.89
High: 0.9199
Volume: 146,646
  
Pre. Close: 0.908
Low: 0.8511
Market Cap: 29(M)
Technical analysis
2025-02-12 4:45:58 PM
Short term     
Mid term     
Targets 6-month :  7.11 1-year :  10.92
Resists First :  6.09 Second :  9.35
Pivot price 1.05
Supports First :  0.82 Second :  0.69
MAs MA(5) :  0.88 MA(20) :  1.74
MA(100) :  0 MA(250) :  0
MACD MACD :  -1.6 Signal :  -1.8
%K %D K(14,3) :  4.2 D(3) :  2.3
RSI RSI(14): 25.6
52-week High :  19.51 Low :  0.82
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ JUNS ] has closed above bottom band by 24.0%. Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.92 - 0.93 0.93 - 0.93
Low: 0.84 - 0.85 0.85 - 0.85
Close: 0.87 - 0.88 0.88 - 0.89
Company Description

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Headline News

Fri, 07 Feb 2025
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN

Tue, 04 Feb 2025
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire

Tue, 04 Feb 2025
Inside Jupiter's $50B Market Strategy: NIH Funding Secured, Phase 2 Trials Set for Revolutionary CNS Treatment - StockTitan

Mon, 03 Feb 2025
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com

Thu, 30 Jan 2025
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire

Mon, 13 Jan 2025
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 33 (M)
Shares Float 0 (M)
Held by Insiders 54.4 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -0.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.22
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.03
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -44.13
PEG Ratio 0
Price to Book value -4.02
Price to Sales 0
Price to Cash Flow -58.79
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android